B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
Blymphocytes
chemokineCXCL13
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
immunotherapy
knockout (KO)
programmed death-ligand 1 (PD-L1)
the Cancer Genome Atlas melanoma (TCGA)
toll-like receptor 7/8
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
10
2021
accepted:
20
04
2022
entrez:
20
6
2022
pubmed:
21
6
2022
medline:
22
6
2022
Statut:
epublish
Résumé
Immunotherapies such as checkpoint blockade therapies are known to enhance anti-melanoma CD8
Identifiants
pubmed: 35720386
doi: 10.3389/fimmu.2022.794684
pmc: PMC9204262
doi:
Substances chimiques
Antibodies
0
Toll-Like Receptor 7
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
794684Subventions
Organisme : NCI NIH HHS
ID : P50 CA093459
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
Copyright © 2022 Singh, Roszik, Saini, Singh, Bavisi, Wang, Vien, Yang, Kundu, Davis, Bover, Diab, Neelapu, Overwijk, Rai and Singh.
Déclaration de conflit d'intérêts
Author WO was employed by company Nektar Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Commun. 2019 Sep 13;10(1):4186
pubmed: 31519915
Lancet. 2005 Jun 11-17;365(9476):2003; author reply 2004-5
pubmed: 15950709
Immunol Res. 2013 Dec;57(1-3):335-53
pubmed: 24293007
Pigment Cell Melanoma Res. 2015 Jul;28(4):453-63
pubmed: 25847062
J Invest Dermatol. 2019 Jul;139(7):1422-1424
pubmed: 31230637
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
J Immunol. 2015 Sep 15;195(6):2571-9
pubmed: 26268653
Transpl Int. 2013 Sep;26(9):919-27
pubmed: 23841454
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
pubmed: 9843981
J Immunol. 2010 Apr 1;184(7):4006-16
pubmed: 20194720
Eur J Surg Oncol. 2017 Mar;43(3):604-611
pubmed: 27769635
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Am J Pathol. 2014 Nov;184(11):3120-9
pubmed: 25173132
Vaccine. 2011 Jul 26;29(33):5434-42
pubmed: 21641953
J Immunol. 2011 Oct 15;187(8):4119-28
pubmed: 21911607
J Immunother Cancer. 2019 Jun 14;7(1):153
pubmed: 31200747
J Immunol. 2014 Nov 1;193(9):4722-31
pubmed: 25252955
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Cancer Immunol Immunother. 2009 Oct;58(10):1535-44
pubmed: 19562338
Adv Pharmacol. 2021;91:111-139
pubmed: 34099106
Mediators Inflamm. 2017;2017:3264217
pubmed: 28848246
Nat Commun. 2017 Sep 19;8(1):607
pubmed: 28928360